Faruqi & Faruqi, LLP is investigating potential claims against Edwards Lifesciences Corporation (EW) for alleged securities law violations. The firm encourages investors who suffered losses exceeding $100,000 in Edwards between February 6, 2024, and July 24, 2024, to contact them directly. The lawsuit alleges that Edwards misled investors about the growth of its core product, Transcatheter Aortic Valve Replacement (TAVR), resulting in a significant stock price decline.